GlassScriptPhysician profile
Linda M Collado
NPI 1588958391
$27,812.62
in general payments reported to CMS, 2019-2025
24 companies · $25K in 2025
The $25K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $250 · 2021: $19.73 · 2022: $329 · 2023: $503 · 2024: $1,226 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $4,373 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,769 · Travel and Lodging: $1,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,958.00 |
| Food and Beverage | $4,373.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,769.00 |
| Travel and Lodging | $1,891.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $23,648.62 | 2025 | Cobenfy |
| Abbvie INC. | $749.16 | 2023-2025 | Vraylar |
| Alkermes, INC. | $641.00 | 2020-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $627.69 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $473.28 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $421.65 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $203.13 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $195.74 | 2022-2025 | Invega Sustenna |
| Lundbeck LLC | $165.05 | 2024-2025 | Rexulti |
| Luye Pharma (USA) LTD. | $136.00 | 2025 | Erzofri Extended-Release |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.46 | 2024 | |
| Indivior INC. | $107.58 | 2022-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $54.27 | 2019 | |
| Axsome Therapeutics, INC. | $53.78 | 2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $36.28 | 2025 | Fanapt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tms Neurohealth Centers INC. | $28.92 | 2025 | Tms Neurohealth Centers INC. |
| Ironshore Pharmaceuticals INC. | $28.11 | 2024 | |
| Idorsia Pharmaceuticals US INC | $25.00 | 2023 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.22 | 2025 | |
| Collegium Pharmaceutical, INC. | $22.08 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $21.53 | 2024 | Xelstrym, Secuado |
| Corium, LLC | $17.62 | 2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $14.45 | 2023 | Trintellix |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Collado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.